Add new claims 47-63.

47. A method of inhibiting appetite, or the gain of weight, in a subject comprising:
identifying a subject in need of inhibiting appetite or weight gain; and
administering an effective amount of an antagonist of melanocyte concentrating hormone (MCH) to said subject, wherein the antagonist binds an MCH receptor.

48. The method of claim 47, wherein the antagonist binds competitively to an MCH receptor.

49. The method of claim 47, wherein the antagonist binds non-competitively to an MCH receptor.

50. The method of claim 47, wherein the antagonist is a peptide analog of MCH.

51. The method of claim 50, wherein the peptide analog has 1, 2, 3, 4, 5 or more residues within the MCH ring structure modified or substituted with a nonconserved amino acid.

52. The method of claim 51, wherein between 1 and 5 residues within the MCH ring structure modified or substituted with a nonconserved amino acid.

B2

53. The method of claim 50, wherein the peptide analog is deleted for any or all of the residues between R1 and R6 or between R18 and R19.

54. The method of claim 51, wherein the peptide analog is deleted for any or all of the residues between R1 and R6 or between R18 and R19.

55. The method of claim 52, wherein the peptide analog is deleted for any or all of the residues between R1 and R6 or between R18 and R19.

56. The method of claim 50, wherein the peptide analog has least 50 % homology with MCH.

57. The method of claim 50, wherein the peptide analog has least 60 % homology with MCH.

58. The method of claim 50, wherein the peptide analog has least 70 % homology with MCH.

59. The method of claim 50, wherein the peptide analog has least 80 % homology with MCH.

60. The method of claim 50, wherein the peptide analog has least 90 % homology with MCH.

61. The method of claim 47, wherein the antagonist is a non-polypeptide drug or chemical.

B2 cont

62. The method of claim 61, wherein the antagonist binds competitively with MCH.

63. The method of claim 61, wherein the antagonist binds non-competitively with MCH.--